A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 26809712)

Published in Mol Neurodegener on January 26, 2016

Authors

Thibaut Imberdis1,2,3, Adeline Ayrolles-Torro1,2,3, Alysson Duarte Rodrigues4, Joan Torrent1,2,3, Maria Teresa Alvarez-Martinez5, Gabor G Kovacs6, Jean-Michel Verdier1,2,3, Mike Robitzer4, Véronique Perrier7,8,9

Author Affiliations

1: Université Montpellier, Montpellier, F-34095, France.
2: Inserm, U1198, Montpellier, F-34095, France.
3: EPHE, Paris, F-75007, France.
4: Institut Charles Gerhardt Montpellier, UMR 5253 CNRS-UM2-ENSCM-UM, Matériaux Avancés pour la Catalyse et la Santé, ENSCM, 8 rue de l'Ecole Normale, 34296, Montpellier cedex 5, France.
5: Etablissement Confiné d'Expérimentation ECE, CECEMA, US009 Biocampus, UMS 3426, Université Montpellier, Montpellier, F-34095, France.
6: Institute of Neurology, Medical University Vienna, A-1097, Vienna, Austria.
7: Université Montpellier, Montpellier, F-34095, France. veronique.perrier@univ-montp2.fr.
8: Inserm, U1198, Montpellier, F-34095, France. veronique.perrier@univ-montp2.fr.
9: EPHE, Paris, F-75007, France. veronique.perrier@univ-montp2.fr.

Articles cited by this

Novel proteinaceous infectious particles cause scrapie. Science (1982) 24.09

Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A (1993) 10.36

Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med (1998) 9.01

Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci (2003) 8.44

Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet (2001) 5.57

Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry (1991) 5.53

The most infectious prion protein particles. Nature (2005) 5.37

Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell (1989) 4.73

Linkage of prion protein and scrapie incubation time genes. Cell (1986) 3.69

A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95

In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J Mol Biol (2004) 2.59

Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes. Biochemistry (2002) 2.36

Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J Virol (2000) 2.18

Diagnosis of human prion disease. Proc Natl Acad Sci U S A (2005) 2.13

Isolation and characterization of a proteinase K-sensitive PrPSc fraction. Biochemistry (2006) 1.86

Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol (2010) 1.66

Structure-based drug design identifies polythiophenes as antiprion compounds. Sci Transl Med (2015) 1.64

The same primary structure of the prion protein yields two distinct self-propagating states. J Biol Chem (2008) 1.64

In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog (2007) 1.56

Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. Nat Chem Biol (2011) 1.54

High yield purification and physico-chemical properties of full-length recombinant allelic variants of sheep prion protein linked to scrapie susceptibility. Eur J Biochem (2000) 1.35

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol (2013) 1.34

Two amyloid States of the prion protein display significantly different folding patterns. J Mol Biol (2010) 1.16

A case of protease sensitive prionopathy in a patient in the UK. Neuropathol Appl Neurobiol (2009) 1.10

The structural basis for optimal performance of oligothiophene-based fluorescent amyloid ligands: conformational flexibility is essential for spectral assignment of a diversity of protein aggregates. Chemistry (2013) 1.09

Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem (2004) 1.04

The first case of protease-sensitive prionopathy (PSPr) in The Netherlands: a patient with an unusual GSS-like clinical phenotype. J Neurol Neurosurg Psychiatry (2010) 1.04

Molecular pathology of human prion diseases. Int J Mol Sci (2009) 0.94

Effective gene therapy in a mouse model of prion diseases. PLoS One (2008) 0.92

Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther (2007) 0.90

Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity. J Neurosci (2011) 0.88

Pentameric thiophene-based ligands that spectrally discriminate amyloid-β and tau aggregates display distinct solvatochromism and viscosity-induced spectral shifts. Chemistry (2014) 0.85

Full-length prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways. FEBS J (2008) 0.84

Ferulic acid inhibits the transition of amyloid-β42 monomers to oligomers but accelerates the transition from oligomers to fibrils. J Alzheimers Dis (2013) 0.80

Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions. Curr Top Med Chem (2013) 0.78